Laura Gallur

588 total citations
18 papers, 266 citations indexed

About

Laura Gallur is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Laura Gallur has authored 18 papers receiving a total of 266 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 10 papers in Genetics and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Laura Gallur's work include Acute Myeloid Leukemia Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Laura Gallur is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Laura Gallur collaborates with scholars based in Spain, Palestinian Territory and Argentina. Laura Gallur's co-authors include Alberto Álvarez‐Larrán, José Rafael Cabrera, Francisco Javier Peñalver, Dolores Caballero, Carlos Palacio, Juliano Simões de Toledo, José Luís Dapena, Cristina Díaz de Heredia, Josep Castellví and Isidro Jarque and has published in prestigious journals such as Blood, British Journal of Haematology and Haematologica.

In The Last Decade

Laura Gallur

16 papers receiving 258 citations

Peers

Laura Gallur

HEMAT

PFM

GENET

ONCOL

PHEOH

Guy Cantin Canada

Sujaatha Narayanan Canada

Silvia Trappolini Italy

Alessandra Crescimanno Italy

Corentin Orvain France

Claudia Minotto Italy

Francisco Javier Peñalver Spain

JF Tomás Spain

WA Kamps Netherlands

C Stainer United Kingdom

Guy Cantin Canada

Laura Gallur

159 ×0.9

HEMAT

56 ×0.7

PFM

79 ×1.1

GENET

97 ×1.8

ONCOL

24 ×0.5

PHEOH

Citations per year, relative to Laura Gallur Laura Gallur (= 1×) peers Guy Cantin

Countries citing papers authored by Laura Gallur

Since Specialization

Citations

This map shows the geographic impact of Laura Gallur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Gallur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Gallur more than expected).

Fields of papers citing papers by Laura Gallur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Gallur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Gallur. The network helps show where Laura Gallur may publish in the future.

Co-authorship network of co-authors of Laura Gallur

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Gallur. A scholar is included among the top collaborators of Laura Gallur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Gallur. Laura Gallur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Subirá, M L, Laura Palomo, Irene García Medina, et al.. (2024). Ultra-Deep Sequencing of TP53 in Multiple Myeloma: Double-Hit Prevalence and Clinical Phenotype. Blood. 144(Supplement 1). 1935–1935.

Gallur, Laura, Bárbara Tazón‐Vega, Daniel Medina, et al.. (2023). Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis. Blood. 142(Supplement 1). 6457–6457. 1 indexed citations

Gallur, Laura, Bárbara Tazón‐Vega, María Julia Montoro, et al.. (2022). Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression. Blood. 140(Supplement 1). 4024–4025.

Palomo, Laura, Ana Pérez, Bárbara Tazón‐Vega, et al.. (2022). IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice. Blood. 140(Supplement 1). 6966–6967. 4 indexed citations

Palacio, Carlos, Laura Gallur, Bárbara Tazón‐Vega, et al.. (2021). Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis. Leukemia & lymphoma. 62(9). 2202–2210. 3 indexed citations

Gallur, Laura, Elisa Roldán, Fernando Martínez‐Valle, et al.. (2018). Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Annals of Hematology. 97(8). 1349–1356. 32 indexed citations

Pomares, Helena, Guillermo Villacampa, Esther Alonso, et al.. (2018). Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. Leukemia & lymphoma. 60(6). 1522–1527. 1 indexed citations

Nieto, Juan C., Elisa Roldán, María Laura Fox, et al.. (2018). Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab. Blood. 132(Supplement 1). 3402–3402. 1 indexed citations

Purroy, Noelia, Juan Bergua, Laura Gallur, et al.. (2014). Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. British Journal of Haematology. 169(2). 188–198. 42 indexed citations

10.

Purroy, Noelia, Pau Abrisqueta, Cecilia Carpio, et al.. (2012). YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection. Blood. 120(21). 3868–3868. 1 indexed citations

11.

Purroy, Noelia, Juan Bergua, Laura Gallur, et al.. (2011). Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group. Blood. 118(21). 593–593. 2 indexed citations

12.

Palacio, Carlos, et al.. (2010). Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica. 95(6). 936–941. 43 indexed citations

13.

Peñalver, Francisco Javier, Alberto Álvarez‐Larrán, José L. Díez‐Martín, et al.. (2010). Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Annals of Hematology. 89(11). 1073–1080. 54 indexed citations

14.

Peñalver, Francisco‐Javier, Carlos Vilches, Isidro Jarque, et al.. (2007). Influence of the FCGR3A-158 V/F and FCGR2A-131 H/R Polymorphism on the Response to Rituximab Therapy in Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia.. Blood. 110(11). 2097–2097. 1 indexed citations

15.

Peñalver, Francisco Javier, Víctor Jiménez‐Yuste, Manuel Almagro, et al.. (2006). Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Annals of Hematology. 85(6). 400–406. 65 indexed citations

16.

Gallur, Laura, et al.. (2006). Re-Treatment with Rituximab Plus Chemotherapy in Patients with Aggressive Lymphoma Treated Previously with CHOP or CHOP-Like Combinations Plus Rituximab.. Blood. 108(11). 4707–4707. 3 indexed citations

17.

González‐Barca, Eva, Eva Domingo‐Doménech, José Gómez‐Codina, et al.. (2004). First-Line Treatment with Rituximab Improves Survival of Patients with Post-Transplant Lymphoproliferative Disease (PTLD).. Blood. 104(11). 1406–1406. 10 indexed citations

18.

Peñalver, Francisco Javier, Isabel Millán, Alberto Álvarez‐Larrán, et al.. (2004). Mabthera (Rituximab) in the Treatment of 34 Adult Patients with Refractory Autoimmune Hemolytic Anemia (AIHA).. Blood. 104(11). 1619–1619. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact